Following FDA debacle in ’09, Motif lines up a new shot at approval for antibiotic iclaprim
Eight years after the FDA and its experts slapped down Arpida’s antibiotic iclaprim, fearful that the treatment was unsafe to use and the efficacy case was dodgy at best, it’s about to be resubmitted after researchers today heralded a successful non-inferiority Phase III study comparing it favorably with vancomycin.
The news triggered a sharp spike for Motif’s share price $MTFB, which used this antibiotic to jump into late-stage development and Nasdaq.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
